Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain | Addiction Medicine | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Okie  S.  A flood of opioids, a rising tide of deaths.  N Engl J Med. 2010;363(21):1981-1985.PubMedGoogle ScholarCrossref
2.
Centers for Disease Control and Prevention (CDC).  Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008.  MMWR Morb Mortal Wkly Rep. 2011;60(43):1487-1492.PubMedGoogle Scholar
3.
Dhalla  IA, Mamdani  MM, Sivilotti  ML, Kopp  A, Qureshi  O, Juurlink  DN.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.  CMAJ. 2009;181(12):891-896.PubMedGoogle ScholarCrossref
4.
Dunn  KM, Saunders  KW, Rutter  CM,  et al.  Opioid prescriptions for chronic pain and overdose: a cohort study.  Ann Intern Med. 2010;152(2):85-92.PubMedGoogle ScholarCrossref
5.
Bohnert  ASB, Valenstein  M, Bair  MJ,  et al.  Association between opioid prescribing patterns and opioid overdose-related deaths.  JAMA. 2011;305(13):1315-1321.PubMedGoogle ScholarCrossref
6.
Correa  D, Farney  RJ, Chung  F, Prasad  A, Lam  D, Wong  J.  Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations.  Anesth Analg. 2015;120(6):1273-1285.PubMedGoogle ScholarCrossref
7.
Mansukhani  MP, Wang  S, Somers  VK.  Sleep, death, and the heart.  Am J Physiol Heart Circ Physiol. 2015;309(5):H739-H749.PubMedGoogle Scholar
8.
Chou  R, Turner  JA, Devine  EB,  et al.  The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.  Ann Intern Med. 2015;162(4):276-286.PubMedGoogle ScholarCrossref
9.
Menendez  ME, Ring  D, Bateman  BT.  Preoperative opioid misuse is associated with increased morbidity and mortality after elective orthopaedic surgery.  Clin Orthop Relat Res. 2015;473(7):2402-2412.PubMedGoogle ScholarCrossref
10.
Brack  A, Rittner  HL, Stein  C.  Immunosuppressive effects of opioids—clinical relevance.  J Neuroimmune Pharmacol. 2011;6(4):490-502.PubMedGoogle ScholarCrossref
11.
McCarberg  BH, Barkin  RL.  Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.  Am J Ther. 2001;8(3):181-186.PubMedGoogle ScholarCrossref
12.
Moore  RA, Wiffen  PJ, Derry  S, McQuay  HJ.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults.  Cochrane Database Syst Rev. 2011;(3):CD007938.PubMedGoogle Scholar
13.
Pedersen  L, Hansen  AB, Svendsen  K, Skurtveit  S, Borchgrevink  PC, Fredheim  OM.  Reimbursement of analgesics for chronic pain.  Tidsskr Nor Laegeforen. 2012;132(22):2489-2493.PubMedGoogle ScholarCrossref
14.
Carragee  EJ.  Persistent low back pain.  N Engl J Med. 2005;352(18):1891-1898.PubMedGoogle ScholarCrossref
15.
Ray  WA, Meredith  S, Thapa  PB, Hall  K, Murray  KT.  Cyclic antidepressants and the risk of sudden cardiac death.  Clin Pharmacol Ther. 2004;75(3):234-241.PubMedGoogle ScholarCrossref
16.
Ray  WA, Chung  CP, Murray  KT, Cooper  WO, Hall  K, Stein  CM.  Out-of-hospital mortality among patients receiving methadone for noncancer pain.  JAMA Intern Med. 2015;175(3):420-427.PubMedGoogle ScholarCrossref
17.
Ray  WA, Griffin  MR.  Use of Medicaid data for pharmacoepidemiology.  Am J Epidemiol. 1989;129(4):837-849.PubMedGoogle ScholarCrossref
18.
Ray  WA.  Population-based studies of adverse drug effects.  N Engl J Med. 2003;349(17):1592-1594.PubMedGoogle ScholarCrossref
19.
Piper  JM, Ray  WA, Griffin  MR, Fought  R, Daughtery  JR, Mitchel  E  Jr.  Methodological issues in evaluating expanded Medicaid coverage for pregnant women.  Am J Epidemiol. 1990;132(3):561-571.PubMedGoogle Scholar
20.
Dowell  D, Haegerich  TM, Chou  R.  CDC guideline for prescribing opioids for chronic pain–United States, 2016.  JAMA. 2016;315(15):1624-1645.PubMedGoogle ScholarCrossref
21.
Ray  WA.  Evaluating medication effects outside of clinical trials: new-user designs.  Am J Epidemiol. 2003;158(9):915-920.PubMedGoogle ScholarCrossref
22.
Ballantyne  JC, Mao  J.  Opioid therapy for chronic pain.  N Engl J Med. 2003;349(20):1943-1953.PubMedGoogle ScholarCrossref
23.
Park  TW, Saitz  R, Ganoczy  D, Ilgen  MA, Bohnert  AS.  Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.  BMJ. 2015;350:h2698.PubMedGoogle ScholarCrossref
24.
Westreich  D, Cole  SR, Tien  PC,  et al.  Time scale and adjusted survival curves for marginal structural cox models.  Am J Epidemiol. 2010;171(6):691-700.PubMedGoogle ScholarCrossref
25.
Shadish  WR, Steiner  PM.  A primer on propensity score analysis.  Newborn Infant Nurs Rev. 2010;10:19-26.Google ScholarCrossref
26.
Allison  PD.  Survival Analysis Using SAS: A Practical Guide. 2nd ed. Cary, NC: SAS Institute Inc; 2010.
27.
Ray  WA, Liu  Q, Shepherd  BE.  Performance of time-dependent propensity scores: a pharmacoepidemiology case study.  Pharmacoepidemiol Drug Saf. 2015;24(1):98-106.PubMedGoogle ScholarCrossref
28.
Arbogast  PG, Kaltenbach  L, Ding  H, Ray  WA.  Adjustment for multiple cardiovascular risk factors using a summary risk score.  Epidemiology. 2008;19(1):30-37.PubMedGoogle ScholarCrossref
29.
Arbogast  PG, Ray  WA.  Use of disease risk scores in pharmacoepidemiologic studies.  Stat Methods Med Res. 2009;18(1):67-80.PubMedGoogle ScholarCrossref
30.
Arbogast  PG, Ray  WA.  Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders.  Am J Epidemiol. 2011;174(5):613-620.PubMedGoogle ScholarCrossref
31.
Finnerup  NB, Attal  N, Haroutounian  S,  et al.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.  Lancet Neurol. 2015;14(2):162-173.PubMedGoogle ScholarCrossref
32.
Chou  R, Huffman  LH; American Pain Society; American College of Physicians.  Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline.  Ann Intern Med. 2007;147(7):505-514.PubMedGoogle ScholarCrossref
33.
Moore  RA, Derry  S, Aldington  D, Cole  P, Wiffen  PJ.  Amitriptyline for neuropathic pain and fibromyalgia in adults.  Cochrane Database Syst Rev. 2012;12:CD008242.PubMedGoogle Scholar
34.
Ghinea  N, Lipworth  W, Kerridge  I.  Evidence, regulation and “rational” prescribing: the case of gabapentin for neuropathic pain.  J Eval Clin Pract. 2015;21(1):28-33.PubMedGoogle ScholarCrossref
35.
Yue  HJ, Guilleminault  C.  Opioid medication and sleep-disordered breathing.  Med Clin North Am. 2010;94(3):435-446.PubMedGoogle ScholarCrossref
36.
Zutler  M, Holty  JE.  Opioids, sleep, and sleep-disordered breathing.  Curr Pharm Des. 2011;17(15):1443-1449.PubMedGoogle ScholarCrossref
37.
Lee-Iannotti  J, Parish  JM.  The epidemic of opioid use: implications for the sleep physician.  J Clin Sleep Med. 2014;10(6):645-646.PubMedGoogle Scholar
38.
Solomon  DH, Rassen  JA, Glynn  RJ, Lee  J, Levin  R, Schneeweiss  S.  The comparative safety of analgesics in older adults with arthritis.  Arch Intern Med. 2010;170(22):1968-1976.PubMedGoogle ScholarCrossref
39.
Centers for Disease Control and Prevention (CDC).  Overdose deaths involving prescription opioids among Medicaid enrollees—Washington, 2004-2007.  MMWR Morb Mortal Wkly Rep. 2009;58(42):1171-1175.PubMedGoogle Scholar
Original Investigation
June 14, 2016

Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain

Author Affiliations
  • 1Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee
  • 2Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
  • 3Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee
JAMA. 2016;315(22):2415-2423. doi:10.1001/jama.2016.7789
Abstract

Importance  Long-acting opioids increase the risk of unintentional overdose deaths but also may increase mortality from cardiorespiratory and other causes.

Objective  To compare all-cause mortality for patients with chronic noncancer pain who were prescribed either long-acting opioids or alternative medications for moderate to severe chronic pain.

Design, Setting, and Participants  Retrospective cohort study between 1999 and 2012 of Tennessee Medicaid patients with chronic noncancer pain and no evidence of palliative or end-of-life care.

Exposures  Propensity score–matched new episodes of prescribed therapy for long-acting opioids or either analgesic anticonvulsants or low-dose cyclic antidepressants (control medications).

Main Outcomes and Measures  Total and cause-specific mortality as determined from death certificates. Adjusted hazard ratios (HRs) and risk differences (difference in incidence of death) were calculated for long-acting opioid therapy vs control medication.

Results  There were 22 912 new episodes of prescribed therapy for both long-acting opioids and control medications (mean [SD] age, 48 [11] years; 60% women). The long-acting opioid group was followed up for a mean 176 days and had 185 deaths and the control treatment group was followed up for a mean 128 days and had 87 deaths. The HR for total mortality was 1.64 (95% CI, 1.26-2.12) with a risk difference of 68.5 excess deaths (95% CI, 28.2-120.7) per 10 000 person-years. Increased risk was due to out-of-hospital deaths (154 long-acting opioid, 60 control deaths; HR, 1.90; 95% CI, 1.40-2.58; risk difference, 67.1; 95% CI, 30.1-117.3) excess deaths per 10 000 person-years. For out-of-hospital deaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), the HR was 1.72 (95% CI, 1.24-2.39) with a risk difference of 47.4 excess deaths (95% CI, 15.7-91.4) per 10 000 person-years. The HR for cardiovascular deaths (79 long-acting opioid, 36 control deaths) was 1.65 (95% CI, 1.10-2.46) with a risk difference of 28.9 excess deaths (95% CI, 4.6-65.3) per 10 000 person-years. The HR during the first 30 days of therapy (53 long-acting opioid, 13 control deaths) was 4.16 (95% CI, 2.27-7.63) with a risk difference of 200 excess deaths (95% CI, 80-420) per 10 000 person-years.

Conclusions and Relevance  Prescription of long-acting opioids for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associated with a significantly increased risk of all-cause mortality, including deaths from causes other than overdose, with a modest absolute risk difference. These findings should be considered when evaluating harms and benefits of treatment.

×